Home › Funds › ARISTEIA CAPITAL, L.L.C. › BBIO

ARISTEIA CAPITAL, L.L.C. position in BBIO

BRIDGEBIO PHARMA INC · Health Care

ARISTEIA CAPITAL, L.L.C. reported holding 15,000,000 shares of BBIO (BRIDGEBIO PHARMA INC) in its Q2 2026 13F filing — a position valued at US$25.3M, representing 0.41% of its reported portfolio and ranking #32 among its reported holdings. ARISTEIA CAPITAL, L.L.C. has disclosed BBIO holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)15.00M sh
Reported value held$25.27M
Portfolio Weight0.41%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ARISTEIA CAPITAL, L.L.C.'s BBIO position evolved

ARISTEIA CAPITAL, L.L.C. first disclosed a stake in BBIO in Q3 2023 at 25,280,000 shares (US$19.0M). The position peaked in Q4 2023 at 40,780,000 shares, worth US$34.7M. Across 12 filings, ARISTEIA CAPITAL, L.L.C. increased the stake 6 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 15,000,000 shares valued at US$25.3M — a reduction of -3,500,000 shares quarter over quarter.. Notable position changes include a 100% trim in Q2 2024 (shares were roughly flat over the following quarter), a 4293% increase in Q4 2024 (shares rose 26% over the following quarter), a 118635% increase in Q2 2025 (shares rose 20% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 25.28M $18.96M New
Q4 2023 40.78M $34.74M Add
Q1 2024 30.78M $25.22M Reduce
Q2 2024 76.22K $1.93M Reduce
Q3 2024 136.59K $3.48M Add
Q4 2024 6.00M $6.31M Add
Q1 2025 23.58K $815.23K Reduce
Q2 2025 28.00M $26.21M Add
Q3 2025 6.00M $8.43M Reduce
Q4 2025 10.00M $18.89M Add
Q1 2026 18.50M $33.33M Add
Q2 2026 15.00M $25.27M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BBIO and 13F data

BBIO (BRIDGEBIO PHARMA INC) is a Health Care company. 48 other funds we track also report a position in BBIO — the largest reported positions include Jupiter Topco LLC (US$1.05B), Janus Henderson Group (US$978.6M), Farallon Capital Management (US$800.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BBIO

All BBIO fund holders →

FAQ

How long has ARISTEIA CAPITAL, L.L.C. held BBIO?

ARISTEIA CAPITAL, L.L.C. has disclosed BBIO holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is ARISTEIA CAPITAL, L.L.C.'s current position in BBIO?

As of Q2 2026, ARISTEIA CAPITAL, L.L.C. holds 15.00M shares of BBIO (BRIDGEBIO PHARMA INC), valued at $25.27M, representing 0.41% of its reported portfolio and ranking #32.

Has ARISTEIA CAPITAL, L.L.C. been buying or selling BBIO?

In the latest 13F filing (Q2 2026), ARISTEIA CAPITAL, L.L.C. reduced its position in BBIO. The position peaked in Q4 2023 at 40.78M shares.

Which other funds hold BBIO?

Other major institutional holders of BBIO include Jupiter Topco LLC, Janus Henderson Group, Farallon Capital Management, among 48 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.